Janus Intl Gr (NYSE:JBI) reported quarterly earnings of $0.11 per share which missed the analyst consensus estimate of $0.13 by 15.38 percent. This is a 68.57 percent decrease over earnings of $0.35 per share from the same period last year. The company reported quarterly sales of $187.79 million which beat the analyst consensus estimate of $175.40 million by 7.06 percent. This is a 33.81 percent increase over sales of $140.34 million the same period last year.
VBL Therapeutics Announces Completion Of Enrollment In Oval Phase 3 Registration-enabling Trial Of Ofra-Vec In Ovarian Cancer And Unanimous Recommendation By Independent Data Safety Monitoring Committee To Continue Study As Planned
VBL Therapeutics (NASDAQ:VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today
